5 Simple Statements About ABBV-744 clinical trial phase 1 results Explained
These side effects had been notably milder in comparison with an inhibitor of both bromodomains. A detailed molecular analysis also unveiled that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes. ― Stephen TaylorFeasible new approaches with the prognosis and treatment of AML. (A) The identification of su